comparemela.com

Latest Breaking News On - Parde annual report - Page 1 : comparemela.com

Pardes Biosciences Reports First Quarter 2023 Financial

CARLSBAD, Calif., May 05, 2023 (GLOBE NEWSWIRE) Pardes Biosciences, Inc. (NASDAQ: PRDS) today reported financial results for the first quarter ended.

Pardes bioscienceThomasg wiggansPardes biosciencesPardes biosciences incExchange commissionChief executive officerParde quarterly reportPardes bioscience investorsPrivate securities litigation reform actParde annual reportQuarterly reportFinancial informationMonths ended marchNasdaq prdsPardes biosciences

Pardes Biosciences Announces Commencement of Phase 2 Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections

Phase 2 trial expected to enroll 210 patients at approximately 75 sites to evaluate antiviral activity, safety, and efficacy of PBI-0451 versus placebo Interim data from Phase 2 anticipated in Q1. | September 13, 2022

United statesPardes biosciencesStephen jasperPatrick obrienPardes bioscienceTom wiggansExchange commissionGilmartin groupPardes biosciences incGlobenewswire incChief executive officerPardes bioscience investorsPrivate securities litigation reform actParde annual reportQuarterly reportNc stock exchange

Pardes Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update

CARLSBAD, Calif., Aug. 15, 2022 Pardes Biosciences, Inc. , a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel oral antiviral drug candidate for the treatment and. | August 15, 2022

Pardes biosciencesStephen jasperPatrick obrienPardes bioscienceThomasg wiggansExchange commissionGilmartin groupPardes biosciences incGlobenewswire incFast trackChief executive officerPardes bioscience investorsPrivate securities litigation reform actParde annual reportQuarterly reportFinancial information

vimarsana © 2020. All Rights Reserved.